Contrary to recent reports, researchers found that osteoarthritis patients who had total knee or hip joint replacement surgery, known as arthroplasty, were at increased risk of heart attack (myocardial infarction) in the early post-operative period. However, findings indicate that long-term risk of heart attack did not persist, while the risk for venous thromboembolism — blood clot in veins and lungs — remained years after the procedure. Visit the Source Site
Twenty-five percent of men currently taking Finasteride or Dutasteride, popularly known as Proscar and Avodart, for the treatment of benign prostate enlargement, appear not to benefit from taking these medications. Those prescribed Propecia or Avodart for male pattern hair loss (known as alopecia) are also at risk for adverse events elicited by these drugs. Visit the Source Site
Osteoarthritis is the most common form of joint disease worldwide. Now, scientists have taken a leaf out of nature’s book in an attempt to develop effective stem cell treatment for osteoarthritis, a condition which affects millions of people in the UK alone. Visit the Source Site
(Reuters Health) – Compared to other kinds of fat, extra virgin olive oil may have healthier effects on levels of blood sugar and bad cholesterol after meals, according to an Italian study.
That may explain why a traditional Mediterranean diet rich in olive oil is linked to lower risk of cardiovascular disease, researchers say.
“Lowering (post-meal) blood glucose and cholesterol may be useful to reduce the negative effects of glucose and cholesterol on the cardiovascular system,” lead study author Francesco Violi, a researcher at Sapienza University in Rome, said by email.
A new diabetes pill from Eli Lilly and Co and Boehringer Ingelheim cut risk of heart attack, stroke and death in a closely watched study, the first glucose-lowering drug to show such protective results in a large cardiovascular trial, the drugmakers said on Thursday.
Besides burnishing the image of the year-old drug, Jardiance, the results could raise the profile of rival new drugs in the same class of medicines called SGLT2 inhibitors, such as Johnson & Johnson’s Invokana and AstraZeneca Plc’s Farxiga.
“In the little known world of medical lending, financiers invest in operations to remove pelvic implants from women suing device makers – and reap an inflated share of the payouts when cases settle,” Reuters reports in an eye-opening story.
StemExpress, the firm that worked with Planned Parenthood patients to facilitate medical uses of fetal tissue, has ended its relationship with the women’s health organization to escape the political firestorm. (Los Angeles Times)
GOP lawmakers are asking the Justice Department to provide information on laws banning for-profit sale of fetal tissue, and to report on their “history of enforcement” of those laws, according to CBS News.
Hospira today announced that InflectraTM (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS).
Inflectra has been registered in Australia for the treatment of eight inflammatory conditions: rheumatoid arthritis (RA); psoriatic arthritis; ankylosing spondylitis (AS); adult and paediatric Crohn’s disease; refractory fistulising Crohn’s disease; adult and paediatric ulcerative colitis; and plaque psoriasis.
Inflectra is a biosimilar medicine formulated to deliver comparable efficacy, safety and quality as the originator biologic, Remicade® (infliximab) – a mAb therapy that cost the PBS more than $100 million last year.